Pulmonary hypertension (PH) can be challenging for healthcare professionals to diagnose because of its vague symptoms, such as fatigue and shortness of breath. These symptoms, which may be mild ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

[80] ARIES-1 randomized 202 patients with PAH to either placebo or ambrisentan 5 mg, or 10 mg once daily, and ARIES-2 randomized 192 PAH patients to ambrisentan 2.5 mg or 5 mg once daily for a ...

Typically, generic drugs cost less than brand-name drugs. Tadalafil is available as brand names Adcirca and Alyq, which treat PAH, and Cialis, which treats ED, BPH, or both. If your doctor ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...